Part One Research About The Mechanism Of Action Of Mifepristone On Proliferation And Apoptosis Of Breast Cancer Cell Lines

OBJECTIVE: Attack rate of breast cancer is more and more at present time,as about 1,300,000 new case and a rising death rate ever year. Breast cancer has become one of the principal diseases that threate the life of women severely. Besides conventional operation, radiotherapy, chemoth- erapy, endocrine therapy is reconstructed increasingly. Endocrine therapy occupies about 55 percent in American,20 percent in Japan and only 4 percent in China. Now, therapeutic effect of endocrine therapy medicines, such as tamoxifen(TAM), fadrozol,have been affirmed,but itself have many side effects, e.g. TAM's endometrium thickening, even endometrial cancer and high blood fat, thrombogenesis, adiposis hepatica, fadrozol's destruction of bone. To find a effective, little adverse reaction endocrine therapy medicine is the starting point of our study.In 1981,mifepristone(MIF) a derivation of 19-nortestosterone,was first produced by Roussel Uclaf, France,and has drastic chemical force to progesteronereceptor(PR) and glucocorticoidreceptor(GR). MIF is a multiplicity antagon, at first,it shows antiprogesterone and antiglucocorti- coid,second it shows progesterone(P), glucocorticoid(G) effect partly. Recent years had find MIF has antitumer effect and can reinforce the therapeutic effect of anticancer drugs and other uses. P can stimulate proliferation of breast cancer cells in vitro,this may relate to breast cancer metastasis. AS receptor antagonis of P, MIF can be used in the treatment of breast cancer. In vitro, the investigators showed that the...